[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:sezary-syndrome":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":122,"states":123},"Sezary Syndrome",18,16,[8,16,22,29,36,42,48,54,60,66,72,78,84,90,96,102,108,115],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04930653","Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma",[12],"Phase 2","RECRUITING","2026-08-03T03:09:55.663340Z","2026-05-05T02:43:29.525932Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT05956041","Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed\u002FRefractory Cutaneous T-cell Lymphomas",[12],"2026-08-26T02:18:25.327036Z","2026-05-05T02:43:27.623186Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT05296304","A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides",[26],"Phase 1","2026-08-26T02:18:31.944757Z","2026-05-05T02:43:26.900130Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT03011814","Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma",[33],"Phase 1\u002FPhase 2","2026-08-26T02:19:13.549512Z","2026-06-17T02:29:30.057758Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT04256018","Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome",[12],"2026-08-26T02:16:05.813655Z","2026-05-05T02:43:28.661336Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT03587844","Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients",[12],"2026-08-26T02:15:47.754948Z","2026-05-05T02:43:28.021905Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT07192471","A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma",[26],"2026-08-26T02:17:59.904383Z","2026-07-05T05:32:16.661363Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT05079282","Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma",[26],"2026-08-26T02:17:12.307088Z","2026-05-05T02:43:29.642831Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT05996185","Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma",[12],"2026-08-26T02:16:52.995882Z","2026-05-05T02:43:28.341848Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT05967416","Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma",[26],"2026-08-26T02:15:43.339060Z","2026-05-05T02:43:27.815843Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT03125642","Auto Stem Cell Transplant for Lymphoma Patients",[12],"2026-08-26T02:16:13.426928Z","2026-05-05T02:43:26.753431Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT07003100","A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab",[],"2026-08-26T02:15:58.452248Z","2026-05-13T02:55:06.604967Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT05157581","Extracorporeal Photopheresis in Sezary Syndrome",[],"2026-08-26T02:16:23.080181Z","2026-05-13T02:55:06.293294Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT02840747","Tissue Repository: CTCL Collection Protocol",[],"2026-08-26T02:16:33.772093Z","2026-05-13T02:55:06.102573Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT02848274","ID Of Prognostic Factors In Mycosis Fungoides\u002FSezary Syndrome",[],"2026-08-26T02:17:29.353236Z","2026-05-13T02:55:06.101874Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT05978141","A Registry for People With T-cell Lymphoma",[],"2026-08-26T02:16:20.336282Z","2026-05-13T02:55:06.403613Z",{"nct_id":109,"title":110,"phases":111,"status":112,"updated_at":113,"content_modified":114},"NCT07682792","Golidocitinib in Patients With Mycosis Fungoides\u002FSézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia",[12],"NOT_YET_RECRUITING","2026-08-26T02:19:16.454910Z","2026-07-19T19:36:05.150066Z",{"nct_id":116,"title":117,"phases":118,"status":119,"updated_at":120,"content_modified":121},"NCT03690011","Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells",[26],"ACTIVE_NOT_RECRUITING","2026-08-03T03:05:09.265674Z","2026-05-05T02:43:27.128098Z",[],[124,128,132,135,139,143,146,150,154,158,161],{"state":125,"count":126,"slug":127},"California",10,"california",{"state":129,"count":130,"slug":131},"New York",8,"new-york",{"state":133,"count":130,"slug":134},"Texas","texas",{"state":136,"count":137,"slug":138},"Pennsylvania",7,"pennsylvania",{"state":140,"count":141,"slug":142},"Georgia",6,"georgia",{"state":144,"count":141,"slug":145},"New Jersey","new-jersey",{"state":147,"count":148,"slug":149},"Missouri",5,"missouri",{"state":151,"count":152,"slug":153},"Massachusetts",4,"massachusetts",{"state":155,"count":156,"slug":157},"Connecticut",3,"connecticut",{"state":159,"count":156,"slug":160},"Florida","florida",{"state":162,"count":156,"slug":163},"Ohio","ohio"]